Sirnaomics Ltd. (“Sirnaomics” or the “Company”, stock code: 2257) announced that its Board of Directors voluntarily established an External Scientific Advisory Board (the “Scientific Advisory Board” or “SAB”) on 21 July 2026. The SAB is dedicated to providing independent, authoritative scientific guidance for the Group’s therapeutic pipeline R&D programs, bolstering the Company’s sustained in-depth exploration and innovative breakthroughs in the field of RNA therapeutics.

This newly formed Scientific Advisory Board brings together five internationally renowned, preeminent interdisciplinary authorities, constructing a top-tier empowerment matrix that integrates four critical dimensions: foundational technology breakthroughs, clinical strategic planning, cross-border regulatory compliance, and global business development.

The SAB lineup includes the founder of the PNP delivery platform and the original inventor of GalNAc-targeted delivery technology, reinforcing the proprietary core technology moat for the Company’s self-developed nucleic acid drugs. Two senior clinical academic leaders, with deep expertise in cutting-edge translational research in oncology, cardiovascular and metabolic diseases, excel at pipeline top-level strategic planning and clinical value reshaping. The team also incorporates a former senior FDA reviewer, highly proficient in the regulatory systems of both the U.S. FDA and China’s NMPA, capable of precisely formulating end-to-end strategies for new drug application and approval in both regions.

All members have held senior positions at multinational pharmaceutical corporations (MNCs), are deeply embedded in the global biopharmaceutical industry ecosystem, and possess extensive international networks and hands-on experience in business cooperation – a core and highly valuable advantage of this SAB.

Leveraging the members’ profound MNC backgrounds and global industry resource networks, the SAB will deeply empower the Company’s business development (BD) activities. It will precisely broker connections with top-tier overseas pharmaceutical companies and efficiently drive the implementation of various industrial collaborations, including cross-border licensing, joint R&D, commercialization partnerships, and overseas market distribution. This will open up critical pathways for Sirnaomics’ global commercial layout, forming a full-chain, closed-loop support system spanning technology R&D, clinical development, regulatory filing and approval, to overseas commercial cooperation, thereby comprehensively solidifying the Company’s core competitiveness for international development.

The profiles of the five experts are as follows
(listed in no particular order):

● Dr. David Evans, Ph.D.
Co-founder of the Company and core developer of the Group’s polypeptide nanoparticle (PNP) delivery platform, bringing over 30 years of specialized experience in RNA mechanism research and novel drug discovery. Dr.David Evans earned his B.Sc. (Hons) and Ph.D. in Biochemistry from Imperial College London and completed postdoctoral fellowships at the University of Maryland and St.Louis University School of Medicine.  

● Dr. Dmitry Samarsky, Ph.D.
Distinguished specialist in oligonucleotide therapeutics,former Chief Technology Officer of the Company and inventor of the proprietary GalAhead™ delivery platform, with a wealth of expertise in novel delivery system iteration and optimization. Dr. Dmitry Samarsky earned his Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts and conducted post-doctoral training at UMass Medical School as an H. Arthur Smith Fellow.

● Dr. Johnson Yiu-Nam Lau, MBBS, MD, FRCP, FHKCP, FHKAM
Seasoned physician and biotech executive with extensive experience in securing regulatory approvals for multiple novel drugs from the U.S. Food and Drug Administration (‘‘FDA’’), the European Medicines Agency (EMA), and the Therapeutic Goods Administration (TGA), along with deep insights into biotech capital operations and commercial product management. Dr. Johnson Yiu-Nam Lau earned his medical degrees (MBBS, MD) from the University of Hong Kong and is a Fellow of the Royal College of Physicians (London), the Hong Kong Academy of Medicine and the Hong Kong College of Physicians.

● Dr. Archie Tse, M.D., Ph.D.
President, Head of Research & Development at Adlai Nortye, Senior executive leader in oncology R&D, with distinguished experience working at Merck, Daiichi-Sankyo and CStone Pharmaceuticals, specializing in the research and industrial transformation of small-molecule drugs, monoclonal antibodies, ADCs and tumor vaccines. Dr. Archie Tse earned his Doctor of Medicine, Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California.

● Dr. Audrey Jia, M.D., Ph.D.
Former senior CMC reviewer at the FDA, possessing authoritative expertise in global cross-border regulatory strategies for Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) filings, as well as end-to-end Good Manufacturing Practice (GMP) compliance management. Dr. Audrey Jia trained as a medical professional at Peking University before earning her Ph.D. at Emory University and master’s degree in Regulatory Affairs at Johns Hopkins University. She is certified by the Educational Commission for Foreign Medical Graduates (ECFMG) and has passed the United States Medical Licensing Examination (USMLE).

The Company extends its sincere welcome to the five experts. The diverse industry experience and global strategic vision of the SAB members will bring objective, independent, and high-value professional insights to the Group. This will help continuously enrich and optimize the therapeutic pipeline and further expand the Group’s global high-end scientific research collaboration ecosystem.